CTI BioPharma Corp (NASDAQ:CTIC) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.87 and traded as high as $0.83. CTI BioPharma shares last traded at $0.81, with a volume of 28,533 shares.
The stock’s fifty day moving average price is $0.70 and its 200 day moving average price is $0.87. The company has a quick ratio of 3.15, a current ratio of 3.15 and a debt-to-equity ratio of 0.20.
CTI BioPharma (NASDAQ:CTIC) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.19). The company had revenue of $0.42 million during the quarter. CTI BioPharma had a negative net margin of 225.01% and a negative return on equity of 77.77%.
CTI BioPharma Company Profile (NASDAQ:CTIC)
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.
Featured Article: Earnings Per Share
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.